Welcome to our dedicated page for Respirerx Pharma news (Ticker: RSPI), a resource for investors and traders seeking the latest updates and insights on Respirerx Pharma stock.
Respirex Pharma (RSPI) delivers innovative therapeutic solutions through cutting-edge biopharmaceutical research. This news hub provides investors and industry professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives shaping the company’s trajectory.
Access a centralized repository of press releases and verified news covering RSPI’s advancements in neurology, respiratory therapies, and translational medicine. Track critical updates including clinical trial progress, research partnerships, and peer-reviewed publication highlights that underscore the company’s scientific rigor.
Our curated collection ensures you stay informed about RSPI’s operational achievements without speculative commentary. Bookmark this page for efficient monitoring of earnings announcements, intellectual property developments, and collaborative ventures driving therapeutic innovation.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announced the publication of research on KRM-II-81, a novel analgesic, in the book The Neurobiology, Physiology, and Psychology of Pain. This compound selectively potentiates GABAA receptors, showing significant analgesic efficacy without common opioid side effects. KRM-II-81 demonstrated comparable or superior analgesic effects in animal models compared to traditional analgesics, while avoiding tolerance, dependence, and respiratory depression. The company is optimistic about KRM-II-81's potential to address pain management amidst the opioid crisis.
RespireRx Pharmaceuticals (OTCQB: RSPI) announced two significant peer-reviewed studies led by Dr. David Fuller, demonstrating the potential of AMPAkines CX1739 and CX717 to enhance motor nerve activity and muscle function in spinal cord injury models. The first study highlights CX717's effectiveness in increasing motor output in rats, while the second showcases improvements in diaphragm activity and overall motor functioning in awake rats post-spinal injury. These findings bolster hopes for AMPAkines as therapeutic alternatives for spinal cord injury recovery, paving the path toward human clinical trials.
On November 22, 2021, RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announced the availability of a podcast featuring CEO Timothy Jones. Recorded on October 21, 2021, and released by OTC Markets on November 17, 2021, the podcast discusses the company's business units, including pharmaceutical cannabinoids and neuromodulators, along with targeted therapeutic indications such as Obstructive Sleep Apnea and ADHD. Notably, potential offerings pursuant to Regulation A were not discussed. The company emphasizes its commitment to addressing unmet medical needs through innovative therapies.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) has released a video interview featuring CFO Jeff Margolis, providing insights into the company's structure, programs, and market opportunities. The interview is accessible to the public on November 4, 2021, via ProActive Investors and RespireRx's website. Margolis discussed the upcoming Regulation A offering and the preliminary offering amount of 250 million shares priced between $0.02 and $0.03 per share, aiming for a maximum raise of $7.5 million. This offering is pending SEC qualification.
RespireRx Pharmaceuticals (OTCQB: RSPI) will participate in the Access China Biotech 2021 Digital conference from June 9-14, 2021. This event facilitates connections between Western pharmaceutical and biotech leaders and Chinese companies. RespireRx focuses on developing treatments for neurological disorders, specifically targeting conditions like obstructive sleep apnea and ADHD. The company aims to advance its innovative drug candidates based on cannabinoids and neuromodulators. Their corporate presentation is available online for stakeholders.
RespireRx Pharmaceuticals (OTCQB: RSPI) announces a significant advancement in spinal cord injury treatment. At the Annual Experimental Biology Conference, researchers presented findings demonstrating that low doses of AMPAkines CX717 and CX1739 effectively increase diaphragm activity and tidal volume in non-anesthetized rats post-cervical spinal cord injury. The ongoing collaboration with the University of Florida is focused on developing a Phase 2 clinical trial aimed at restoring motor functions in patients with spinal cord injury. This research highlights the potential of AMPAkines as a groundbreaking treatment option.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announced significant advancements in its drug development programs targeting neurological disorders. The company is preparing to publish a review on its GABAkine compound, KRM-II-81, which shows promise in treating epilepsy, chronic pain, anxiety, and depression. Additionally, ongoing collaborations are expected to enhance AMPAkines for spinal cord injury recovery, and innovative formulations of dronabinol are in preclinical development for obstructive sleep apnea. While progress is noted, key compounds have yet to enter human trials, indicating risk in their future success.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) has successfully up-listed from the OTC Pink Market to the OTCQB Venture Market, effective February 8, 2021. The company's ticker symbol has reverted to RSPI from RSPID. RespireRx focuses on developing innovative treatments for conditions such as obstructive sleep apnea and ADHD, leveraging its two main drug platforms: ResolutionRx (pharmaceutical cannabinoids) and EndeavourRx (neuromodulators). The management is considering separating these platforms into subsidiaries to optimize value and attract funding.
RespireRx Pharmaceuticals has been uplisted from the OTC Pink Market to the OTCQB Venture Market as of February 8, 2021. The ticker symbol has changed back to RSPI from RSPID. The company's focus is on developing treatments for various disorders including obstructive sleep apnea, ADHD, and chronic pain through two main drug platforms: ResolutionRx and EndeavourRx. RespireRx aims to enhance asset value by potentially establishing formal subsidiaries and engaging in strategic partnerships and business development efforts. However, there are no guarantees regarding successful transactions.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announced the publication of a review on CX717, an ampakine that enhances motor nerve function post-spinal cord injury, by Dr. David Fuller. The article in Experimental Neurology highlights CX717's ability to improve phrenic motor nerve activity over 8 weeks, suggesting potential benefits for spinally injured patients. Chief Scientific Officer Arnold Lippa emphasized the intention to advance this research towards human clinical trials, underscoring the company's focus on neuromodulators for treating diverse neurological disorders.
